Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TG4010 plus chemotherapy in advanced non-small cell lung cancer
2005-001015-22Phase 2Completed
- Sponsor
- Transgene SA
- Start
- Nov 2005
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of TG4010 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Transgene SA. Primary endpoint: Progression-free survival at 6 months. Started Nov 2005; status: completed.
02
Drugs
TG4010
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2005-001015-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001015-22.